NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

CompletedPhase 3

Sponsor: Sanofi

Conditions: Acquired Thrombotic Thrombocytopenic Purpura

Interventions: Caplacizumab, Standard of Care

Countries: United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel

The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Completed the Final (28 day) follow-up visit in Study ALX0681-C301.
2. \>= 18 years of age at the time of signing the informed consent form.
3. Provided informed consent prior to initiation of any study specific activity/procedure.

Exclusion Criteria:

1. Not being able/willing to comply with the study protocol procedures.
2. Currently enrolled in a clinical study with another investigational drug or device.

Locations (45)

St Louis, Missouri, United States
Valhalla, New York, United States
Durham, North Carolina, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Greenville, South Carolina, United States
Vienna, Austria
Antwerp, Belgium
Brussels, Belgium
La Louvière, Belgium
Leuven, Belgium
Halifax, Canada
Québec, Canada
Toronto, Canada
Brno, Czechia
Olomouc, Czechia
Caen, France
Lille, France
Marseille, France
Paris, France
Paris, France
Budapest, Hungary
Debrecen, Hungary
Haifa, Israel
Jerusalem Region, Israel
Nahariya, Israel
Catania, Italy
Milan, Italy
+ 15 more on CT.gov